A fit patient has untreated BRAF V600-mutant metastatic melanoma with rapidly progressive bulky liver disease, rising LDH and impending hepatic

Question

A fit patient has untreated BRAF V600-mutant metastatic melanoma with rapidly progressive bulky liver disease, rising LDH and impending hepatic compromise. There is judged to be insufficient time for an adequate immune response. Which first-line strategy most closely follows NICE NG14?

Accepted Answer

Dabrafenib–trametinib as a rapid-response BRAF/MEK combination

Answer

Pembrolizumab monotherapy to reduce toxicity while retaining immunotherapy benefit

Answer

Vemurafenib monotherapy to maximise the speed of tumour response

Answer

Nivolumab–ipilimumab as the usual default combination immunotherapy

Answer

Dacarbazine chemotherapy to avoid early immune-related treatment toxicity

CheckMate 067 Long-term — SCE Medical Oncology MCQ

A fit patient has untreated BRAF V600-mutant metastatic melanoma with rapidly progressive bulky liver disease, rising LDH and impending hepatic compromise. There is judged to be insufficient time for an adequate immune response. Which first-line strategy most closely follows NICE NG14?